Logo image of TGTX

TG THERAPEUTICS INC (TGTX) Stock Fundamental Analysis

NASDAQ:TGTX - Nasdaq - US88322Q1085 - Common Stock - Currency: USD

34.42  +4.33 (+14.39%)

After market: 34.3 -0.12 (-0.35%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to TGTX. TGTX was compared to 571 industry peers in the Biotechnology industry. The financial health of TGTX is average, but there are quite some concerns on its profitability. TGTX is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

TGTX had negative earnings in the past year.
TGTX had a negative operating cash flow in the past year.
In the past 5 years TGTX reported 4 times negative net income.
In the past 5 years TGTX always reported negative operating cash flow.
TGTX Yearly Net Income VS EBIT VS OCF VS FCFTGTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100M -200M -300M

1.2 Ratios

TGTX has a better Return On Assets (-2.45%) than 90.54% of its industry peers.
The Return On Equity of TGTX (-7.48%) is better than 91.43% of its industry peers.
Industry RankSector Rank
ROA -2.45%
ROE -7.48%
ROIC N/A
ROA(3y)-63.44%
ROA(5y)-68.2%
ROE(3y)-159.11%
ROE(5y)-195.79%
ROIC(3y)N/A
ROIC(5y)N/A
TGTX Yearly ROA, ROE, ROICTGTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600

1.3 Margins

With an excellent Gross Margin value of 88.32%, TGTX belongs to the best of the industry, outperforming 91.07% of the companies in the same industry.
TGTX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 88.32%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TGTX Yearly Profit, Operating, Gross MarginsTGTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50K -100K -150K

More info and screens

4

2. Health

2.1 Basic Checks

TGTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
TGTX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for TGTX has been increased compared to 5 years ago.
Compared to 1 year ago, TGTX has an improved debt to assets ratio.
TGTX Yearly Shares OutstandingTGTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M
TGTX Yearly Total Debt VS Total AssetsTGTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

TGTX has an Altman-Z score of 4.80. This indicates that TGTX is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 4.80, TGTX belongs to the best of the industry, outperforming 80.54% of the companies in the same industry.
A Debt/Equity ratio of 1.27 is on the high side and indicates that TGTX has dependencies on debt financing.
TGTX has a Debt to Equity ratio of 1.27. This is amonst the worse of the industry: TGTX underperforms 81.07% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.27
Debt/FCF N/A
Altman-Z 4.8
ROIC/WACCN/A
WACC9.37%
TGTX Yearly LT Debt VS Equity VS FCFTGTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M

2.3 Liquidity

TGTX has a Current Ratio of 4.59. This indicates that TGTX is financially healthy and has no problem in meeting its short term obligations.
TGTX has a Current ratio (4.59) which is comparable to the rest of the industry.
A Quick Ratio of 3.91 indicates that TGTX has no problem at all paying its short term obligations.
TGTX has a Quick ratio (3.91) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.59
Quick Ratio 3.91
TGTX Yearly Current Assets VS Current LiabilitesTGTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

More info and screens

7

3. Growth

3.1 Past

TGTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 60.71%, which is quite impressive.
Looking at the last year, TGTX shows a very strong growth in Revenue. The Revenue has grown by 39.51%.
TGTX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 335.01% yearly.
EPS 1Y (TTM)60.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-97.26%
Revenue 1Y (TTM)39.51%
Revenue growth 3Y1059.22%
Revenue growth 5Y335.01%
Sales Q2Q%-49.41%

3.2 Future

Based on estimates for the next years, TGTX will show a very strong growth in Earnings Per Share. The EPS will grow by 222.31% on average per year.
Based on estimates for the next years, TGTX will show a very strong growth in Revenue. The Revenue will grow by 41.09% on average per year.
EPS Next Y716%
EPS Next 2Y843.82%
EPS Next 3Y467.52%
EPS Next 5Y222.31%
Revenue Next Year38.56%
Revenue Next 2Y54.02%
Revenue Next 3Y48.17%
Revenue Next 5Y41.09%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
TGTX Yearly Revenue VS EstimatesTGTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B
TGTX Yearly EPS VS EstimatesTGTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TGTX. In the last year negative earnings were reported.
TGTX is valuated quite expensively with a Price/Forward Earnings ratio of 38.64.
TGTX's Price/Forward Earnings ratio is rather cheap when compared to the industry. TGTX is cheaper than 92.50% of the companies in the same industry.
TGTX is valuated expensively when we compare the Price/Forward Earnings ratio to 22.44, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 38.64
TGTX Price Earnings VS Forward Price EarningsTGTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -100 -200 -300

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TGTX Per share dataTGTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
TGTX's earnings are expected to grow with 467.52% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y843.82%
EPS Next 3Y467.52%

More info and screens

0

5. Dividend

5.1 Amount

TGTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TG THERAPEUTICS INC

NASDAQ:TGTX (3/3/2025, 7:19:59 PM)

After market: 34.3 -0.12 (-0.35%)

34.42

+4.33 (+14.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2024-11-04/bmo
Earnings (Next)03-03 2025-03-03/bmo
Inst Owners63.58%
Inst Owner Change-4.01%
Ins Owners10.03%
Ins Owner Change3.24%
Market Cap5.36B
Analysts80
Price Target41.09 (19.38%)
Short Float %19.19%
Short Ratio12.57
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)76.13%
Min EPS beat(2)-33.53%
Max EPS beat(2)185.79%
EPS beat(4)2
Avg EPS beat(4)16.52%
Min EPS beat(4)-92.18%
Max EPS beat(4)185.79%
EPS beat(8)4
Avg EPS beat(8)66.09%
EPS beat(12)7
Avg EPS beat(12)50.32%
EPS beat(16)7
Avg EPS beat(16)32.35%
Revenue beat(2)2
Avg Revenue beat(2)4.98%
Min Revenue beat(2)0.65%
Max Revenue beat(2)9.31%
Revenue beat(4)4
Avg Revenue beat(4)7.88%
Min Revenue beat(4)0.65%
Max Revenue beat(4)13.96%
Revenue beat(8)6
Avg Revenue beat(8)37.84%
Revenue beat(12)8
Avg Revenue beat(12)33.32%
Revenue beat(16)9
Avg Revenue beat(16)14.34%
PT rev (1m)-1.44%
PT rev (3m)5.67%
EPS NQ rev (1m)-4.44%
EPS NQ rev (3m)-4.87%
EPS NY rev (1m)-5.09%
EPS NY rev (3m)-45.87%
Revenue NQ rev (1m)1.22%
Revenue NQ rev (3m)1.18%
Revenue NY rev (1m)-3.01%
Revenue NY rev (3m)-2.75%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 38.64
P/S 20.24
P/FCF N/A
P/OCF N/A
P/B 27.88
P/tB 27.88
EV/EBITDA N/A
EPS(TTM)-0.11
EYN/A
EPS(NY)0.89
Fwd EY2.59%
FCF(TTM)-0.18
FCFYN/A
OCF(TTM)-0.18
OCFYN/A
SpS1.7
BVpS1.23
TBVpS1.23
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.45%
ROE -7.48%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 88.32%
FCFM N/A
ROA(3y)-63.44%
ROA(5y)-68.2%
ROE(3y)-159.11%
ROE(5y)-195.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 1.27
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 24%
Cap/Sales 0.01%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.59
Quick Ratio 3.91
Altman-Z 4.8
F-Score2
WACC9.37%
ROIC/WACCN/A
Cap/Depr(3y)48.73%
Cap/Depr(5y)100.24%
Cap/Sales(3y)2.11%
Cap/Sales(5y)66.6%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-97.26%
EPS Next Y716%
EPS Next 2Y843.82%
EPS Next 3Y467.52%
EPS Next 5Y222.31%
Revenue 1Y (TTM)39.51%
Revenue growth 3Y1059.22%
Revenue growth 5Y335.01%
Sales Q2Q%-49.41%
Revenue Next Year38.56%
Revenue Next 2Y54.02%
Revenue Next 3Y48.17%
Revenue Next 5Y41.09%
EBIT growth 1Y97.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year280.46%
EBIT Next 3Y123.33%
EBIT Next 5YN/A
FCF growth 1Y88.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y88.26%
OCF growth 3YN/A
OCF growth 5YN/A